Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem
The article discusses the use of bioanalogues (BAs) in the treatment of rheumatoid arthritis using the example of the comparable efficacy, tolerability and immunogenicity of the original biologic disease-modifying antirheumatic drug (bDMARD) etanercept (ETC) and its BA GP-2015. We discuss the mainte...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1673 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242075473641472 |
|---|---|
| author | N. V. Chichasova A. M. Lila |
| author_facet | N. V. Chichasova A. M. Lila |
| author_sort | N. V. Chichasova |
| collection | DOAJ |
| description | The article discusses the use of bioanalogues (BAs) in the treatment of rheumatoid arthritis using the example of the comparable efficacy, tolerability and immunogenicity of the original biologic disease-modifying antirheumatic drug (bDMARD) etanercept (ETC) and its BA GP-2015. We discuss the maintenance of the improvement achieved when switching from the original ETC to BA. Recommendations of international experts and preliminary recommendations of the Association of Rheumatologists of Russia on the use of BA are given. The frequency of development and negative consequences of the nocebo effect when switching patients to BA are described. Data from randomized controlled trials and clinical practice on the safety of switching patients from original biologics to BA are presented. The economic benefits of introducing BA into the clinical practice of rheumatologists in Europe and Russian Federation are considered. |
| format | Article |
| id | doaj-art-a23e8de8b84341e0aa3fa5e53c7b8e84 |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2024-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-a23e8de8b84341e0aa3fa5e53c7b8e842025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2024-12-011869810610.14412/1996-7012-2024-6-98-1062744Bioanalogues in the treatment of rheumatoid arthritis: current status of the problemN. V. Chichasova0A. M. Lila1V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaThe article discusses the use of bioanalogues (BAs) in the treatment of rheumatoid arthritis using the example of the comparable efficacy, tolerability and immunogenicity of the original biologic disease-modifying antirheumatic drug (bDMARD) etanercept (ETC) and its BA GP-2015. We discuss the maintenance of the improvement achieved when switching from the original ETC to BA. Recommendations of international experts and preliminary recommendations of the Association of Rheumatologists of Russia on the use of BA are given. The frequency of development and negative consequences of the nocebo effect when switching patients to BA are described. Data from randomized controlled trials and clinical practice on the safety of switching patients from original biologics to BA are presented. The economic benefits of introducing BA into the clinical practice of rheumatologists in Europe and Russian Federation are considered.https://mrj.ima-press.net/mrj/article/view/1673rheumatoid arthritisbiologic disease-modifying antirheumatic drugetanerceptbiosimilar gp2015nocebo |
| spellingShingle | N. V. Chichasova A. M. Lila Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem Современная ревматология rheumatoid arthritis biologic disease-modifying antirheumatic drug etanercept biosimilar gp2015 nocebo |
| title | Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem |
| title_full | Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem |
| title_fullStr | Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem |
| title_full_unstemmed | Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem |
| title_short | Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem |
| title_sort | bioanalogues in the treatment of rheumatoid arthritis current status of the problem |
| topic | rheumatoid arthritis biologic disease-modifying antirheumatic drug etanercept biosimilar gp2015 nocebo |
| url | https://mrj.ima-press.net/mrj/article/view/1673 |
| work_keys_str_mv | AT nvchichasova bioanaloguesinthetreatmentofrheumatoidarthritiscurrentstatusoftheproblem AT amlila bioanaloguesinthetreatmentofrheumatoidarthritiscurrentstatusoftheproblem |